BEAM files 8-K; Q3 2025 financial results press release furnished

Rhea-AI Filing Summary

Beam Therapeutics furnished a Form 8-K to announce its financial results for the quarter ended September 30, 2025.

The company issued a press release, furnished as Exhibit 99.1. The information in Item 2.02 and Exhibit 99.1 is furnished and is not deemed filed under Section 18 of the Exchange Act, nor incorporated by reference except as expressly stated.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false000174599900017459992025-11-042025-11-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 4, 2025

BEAM THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

Delaware		001-39208		81-5238376
(State or other jurisdiction		(Commission		(IRS Employer
of incorporation)		File Number)		Identification No.)
238 Main Street
Cambridge, MA				02142
(Address of principal executive offices)				(Zip Code)

(Registrant’s telephone number, including area code): (857) 327-8775

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	BEAM	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 4, 2025, Beam Therapeutics Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended September 30, 2025. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 2.02 as well as in the accompanying Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release Issued by Beam Therapeutics Inc. on November 4, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		BEAM THERAPEUTICS INC.
Date: November 4, 2025		By:	/s/ John Evans
		Name:	John Evans
		Title:	Chief Executive Officer

FAQ

What did BEAM announce in this Form 8-K?

Beam Therapeutics announced financial results for the quarter ended September 30, 2025 via a press release furnished as Exhibit 99.1.

Which SEC form and item did BEAM use?

The company used a Form 8-K under Item 2.02 (Results of Operations and Financial Condition).

Is the press release deemed filed under the Exchange Act?

No. The Item 2.02 information and Exhibit 99.1 are furnished and not deemed filed under Section 18 of the Exchange Act.

Where can investors find the detailed results for BEAM?

They are contained in the press release attached as Exhibit 99.1 to the Form 8-K.

What is the date of the report and earliest event for BEAM?

Both are listed as November 4, 2025.

Who signed the BEAM Form 8-K?

It was signed by John Evans, Chief Executive Officer.

What is BEAM’s trading symbol and exchange?

Trading symbol is BEAM on the Nasdaq Global Select Market.